ARGX · Argenx SE
$1,047.10
+27.61 (+2.71%)
At close · Aug 26
Market Cap
$63.81B
Shares
62.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1,047.10
Open$1,033.83
Day$1,032.85–1,057.91
52W close$663.93–1,047.10
Avg vol 30d305K
Short int1.2M · 1.9% float · 4.4d
Short vol60%
Last earningsDec 31, 2025
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
+16%
above
RSI (14)
70
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+44%
trailing
YTD return
+25%
this year
Relative strength
+31%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $903 › 200d $839 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +84 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.93% of float · ▼ -9.9% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
507 holders — near 3-yr high, broad support
Squeeze score
47
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
35%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
3.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2024
Combined SG&A and R&D spend
· 2024
$2B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
70
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $903 › 200d $839 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +84 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.93% of float · ▼ -9.9% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
507 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $664
Now $1,047 · 100%
Range high $1,047
vs 200-day avg +25%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARGX
this stock
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
|
MRNA
Moderna, Inc.
|
$58.75B | +407.5% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARGX | +1.4% | +18.6% | +43.8% | +22.6% | +24.5% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +1.8% | +13.6% | +31.4% | +20.1% | +12.2% |